Clinical trial
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and…
NCT00191139 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191139 |
|---|---|
| Title | Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC) |
| Official title | A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug, Radiation |
| Interventions | gemcitabine, docetaxel, cisplatin, etoposide, radiation therapy |
| Enrollment | 64 |
| Start date | Mar 1, 2003 |
| Primary completion | Nov 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 17, 2010 |
| Countries | Argentina, China, South Korea, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: